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In the descending analgesia pathway, opioids are known to
disinhibit the projections from the periaqueductal gray (PAG) to
the rostral ventromedial medulla (RVM), leading to suppression of
pain signals at the spinal cord level. The locus coeruleus (LC) has
been proposed to engage in the descending pathway through
noradrenergic inputs to the spinal cord. Nevertheless, how the LC
is integrated in the descending analgesia circuit has remained
unknown. Here, we show that the opioidergic analgesia pathway
is bifurcated in structure and function at the PAG. A knockout as
well as a PAG-specific knockdown of phospholipase C β4 (PLCβ4), a
signaling molecule for G protein-coupled receptors, enhanced
swim stress-induced and morphine-induced analgesia in mice.
Immunostaining after simultaneous retrograde labeling from the
RVM and the LC revealed two mutually exclusive neuronal popu-
lations at the PAG, each projecting either to the LC or the RVM,
with PLCβ4 expression only in the PAG-LC projecting cells that
provide a direct synaptic input to LC-spinal cord (SC) projection
neurons. The PAG-LC projection neurons in wild-type mice turned
quiescent in response to opiates, but remained active in the PLCβ4
mutant, suggesting a possibility that an increased adrenergic func-
tion induced by the persistent PAG-LC activity underlies the enhanced
opioid analgesia in the mutant. Indeed, the enhanced analgesia in the
mutant was reversed by blocking α2-noradrenergic receptors. These
findings indicate that opioids suppress descending analgesia through
the PAG-LC pathway, while enhancing it through the PAG-RVM path-
way, i.e., two distinct pathways with opposing effects on opioid an-
algesia. These results point to a therapeutic target in pain control.
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Pain signals are processed by the ascending sensory circuit andmodulated by the descending analgesic circuit. The peri-
aqueductal gray (PAG) at the midbrain, a key region in the
descending analgesia circuit, is rich in opioid receptors and
generates endogenous opioid analgesic signals (1–6). These sig-
nals are relayed by the rostral ventromedial medulla (RVM) to
the dorsal horn of the spinal cord (SC), where they suppress pain
signals (5, 7). Swimming in warm water induces opioid-dependent,
swim stress-induced analgesia (SSIA) through this circuit (8).
Within the PAG, tonically active GABAergic interneurons inhibit
output neurons that project to the RVM (9, 10). Endogenous
opioids suppress this inhibitory influence of local GABAergic in-
terneurons through mu opioid receptors (μORs), disinhibiting the
antinociceptive drive of the neuronal outputs to the RVM to pos-
itively control descending analgesia (9, 10). Exogenous opioid an-
algesics, such as morphine, also act through these μORs (11, 12).
Phospholipase C (PLC), the enzyme responsible for calcium
mobilization, represents a family of molecules that are coupled
to μORs and affects protein kinase C (PKC) activation (13, 14).
We have previously shown that the PLCβ isoform, PLCβ4, is
required for pain sensory transmission at the thalamic level (15,
16). PLCβ4-PKC signaling is linked to T-type calcium channels
and regulates the firing pattern of thalamocortical neurons to
favor either tonic or burst firing, which efficiently sharpens the
transition between open and closed gate status in pain sensory
processing (15, 17, 18). In situ hybridization data show that
PLCβ4 is abundantly expressed in the PAG (Allen Brain Atlas,
mouse.brain-map.org), but its potential role in the descending
pain control circuit has not been explored.
The locus coeruleus (LC) has recently been proposed to play a
role in endogenous descending pain control through noradren-
ergic inputs, which act via α2-adrenoreceptors to inhibit both primary
afferents and second-order projection neurons in the SC (19–28). The
LC has an afferent connection from the PAG (29, 30), but how the
LC is integrated in the descending analgesia circuits are unresolved.
In this study, motivated by the knowledge of its signaling in-
teractions in the ascending pain pathway (15), we investigated
the role of PLCβ4 in the descending pain system controlled by
opioidergic signals. Our results demonstrate the existence of two
opioidergic circuits that bifurcate at the PAG and exert opposing
effects on descending analgesia.
Results
Opioid-Dependent Analgesia Is Enhanced in PAG-Specific Knockdown
and PLCβ4-Null Mutant Mice. We previously reported that μOR-
positive GABAergic neurons in the PAG mediate the opioidergic
descending analgesia through a mechanism that is dependent on T-
type calcium channels (10). In addition, neuronal burst firing, which
is mediated by T-type calcium channels, is increased in PLCβ4-
deleted neurons (15). We thus hypothesized that a deletion of
PLCβ4 at the PAGmight enhance opioidergic descending analgesia.
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To test this hypothesis, we initially examined baseline thermal
sensitivity in both PLCβ4-knockout [PLCβ4(−/−)] mice and PAG-
specific PLCβ4-knockdown (PLCβ4-shRNA) mice (Fig. 1A).
PLCβ4 knockout significantly increased baseline thermal sensi-
tivity (t = 4.833, P = 0.0003, unpaired two-tailed Student’s t test;
Fig. 1B), a result consistent with a previous study showing that
PLCβ4(−/−) mice exhibit reduced nociception (15, 16). In con-
trast, PAG-specific knockdown of PLCβ4 did not significantly
affect the baseline thermal sensitivity of the mouse (t = 0.964,
P = 0.366, unpaired two-tailed Student’s t test; Fig. 1B). We then
assessed the performance of these mice in the opioid-dependent
swim stress-induced analgesia (SSIA) assay. Interestingly, SSIA
was significantly increased in both PLCβ4(−/−) (t = 4.881, P =
0.0003, unpaired two-tailed Student’s t test; Fig. 1C) and PAG-
specific PLCβ4-knockdown mice (Scrambled-shRNA vs. PLCβ4-
shRNA, t = 8.808, P < 0.001, unpaired two-tailed Student’s t test;
Fig. 1C). In addition, we carried out the 2% formalin-induced
pain test after SSIA in both wild-type and PAG-specific PLCβ4-
knockdown group. Correspondingly, the PAG-specific PLCβ4-
knockdown mice showed significantly reduced inflammatory
pain response compared with the control group [F1,228 = 21.88,
P < 0.001, repeated-measures (RM) ANOVA, SI Appendix, Fig.
S1A]. Immunostaining of the brains after SSIA assays confirmed
a reduction in PLCβ4 expression in the PAG of knockdown mice
(SI Appendix, Fig. S2). These results indicate that PLCβ4 in the
PAG negatively controls opioid-dependent analgesia without
affecting basal thermal sensitization.
Next, we investigated exogenous opioid-induced analgesia in
both wild-type and PLCβ4-defective mice after systemic injection
(10 mg/kg) or PAG infusion (1 μg) of morphine through a can-
nula (SI Appendix, Fig. S3), following a previously described
procedure (10). In wild-type mice, morphine induced a signifi-
cant level of analgesia compared with saline-treated controls
following both systemic injection (F1,15 = 11.88, P = 0.0044, RM
ANOVA) and PAG infusion (F1,32 = 26.57, P < 0.001, RM
ANOVA) (Fig. 1 D and E). Morphine also induced analgesia
compared with saline in PLCβ4(−/−) mice, whether injected
systemically (F1,14 = 74.84, P < 0.001, RM ANOVA) or incused
in the PAG (F1,31 = 69.14, P < 0.001, RM ANOVA) (Fig. 1 D
and E). Notably, the extent of the morphine-induced analgesia
was significantly augmented in the mutant mice compared with
wild-type mice following systemic injection (t = 3.346, P =
0.0065, unpaired two-tailed Student’s t test; SI Appendix, Fig.
S3A) or infusion into the PAG (t = 5.533, P < 0.001, unpaired
two-tailed Student’s t test; SI Appendix, Fig. S3B). These findings
demonstrate that (i) the PAG is a major site for morphine-
induced analgesia and (ii) PLCβ4 deficiency substantially en-
hances PAG-mediated, morphine-induced analgesia.
PLCβ4 Is Selectively Expressed in PAG→LC Circuits, but Not in
PAG→RVM Circuits. The PAG has extensive connectivity with
the brain network that includes not only the RVM (1, 2, 5, 31)
but also the LC, which exerts an analgesic effect (19–22, 29, 30,
32). In an effort to define the relationship between PLCβ4 ex-
pression and PAG-RVM or PAG-LC projection neurons in the
PAG, we injected the retrograde tracers, cholera toxin B (CTB)
and fluorospheres, into the LC and RVM, respectively (SI Ap-
pendix, Fig. S5). Random fluorospheres labeling of PAG-RVM
neurons was observed throughout the entire PAG region, con-
sistent with a previous report (10), whereas retrograde labeling
by CTB from the LC was predominantly observed in the lateral
PAG and ventral PAG. Interestingly, there was no overlap of the
two different fluorescent signals in the same cells, indicating that
the two projection neurons constitute distinct cell populations.
To investigate the expression of PLCβ4 in these two neuronal
populations, we preformed immunohistochemistry for PLCβ4 on
retrograde-labeled sections of both PAG-LC and PAG-RVM
projection neurons. Notably, PLCβ4 was expressed in PAG-LC
projection neurons, which are located in the ventral region, but
not in PAG-RVM projection neurons (Fig. 2 A, B, and D and SI
Appendix, Fig. S6).
In addition, double immunofluorescence experiments per-
formed using tissue from GAD67-GFP mice showed that the
majority of PLCβ4 was detected in neurons that expressed
CamKIIα (calcium/calmodulin-dependent protein kinase II), but
not in neurons that expressed GAD67-GFP (SI Appendix, Fig.
S7), indicating that PLCβ4 was primarily expressed in excitatory
neurons at the PAG. Moreover, double immunostaining for
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Fig. 1. Improved analgesia in PLCβ4(−/−) and PAG-
specific PLCβ4-knockdown mice under endogenous
and exogenous opioidergic conditions. (A) Schematic
depiction of the endogenous opioid condition and
the exogenous opioidergic condition paradigm used
in this study. (B) Test of basal thermal sensitivity us-
ing a hotplate assay. (C) Comparison of the analgesic
effect after the SSIA behavior test. (D and E) Time
course of the effects of morphine-induced analgesia
compared with saline control at the systemic and
PAG level. Values are means ± SEM. (*,#P < 0.05;
**,##P < 0.01; ***,###P< 0.001; n.s., not significant).
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tyrosine hydroxylase (TH), a marker for the LC (33, 34), showed
no PLCβ4 signal in LC neurons (SI Appendix, Fig. S8). These
findings raised the possibility that, because it is selectively
expressed in PAG-LC projections, PLCβ4 may modulate the LC-
mediated analgesia circuit.
PLCβ4-Expressing PAG Neurons Make a Direct Synaptic Input to
LC→SC Projection Neurons. Although it has been well known
that LC neurons receive dense projection from the PAG (29, 30),
and that LC neurons innervate the SC to modulate pain trans-
mission (22), confirmation of the direct connectivity of these
three brain regions has not been achieved. To address this issue,
we used the cTRIO method (29) to examine whether PLCβ4-
expressing PAG neurons make monosynaptic connections to LC-
SC projection neurons (Fig. 3A). We injected a Cre-dependent
CAV2 vector carrying the flippase (Flp) recombinase [CAV2-
FLEX (loxP)-Flp] into the SC of TH-Cre mice. Because CAV2
infects axons and is retrogradely transported to cell bodies, this
combination allows us to express Flp specifically in Cre-expressing
LC-SC projection neurons. We then injected the Flp-activatable
AAV vectors, AAV10-CAG-FLEX (Frt)-TVA-mCherry and
AAV10-CAG-FLEX (Frt)-RG, into the LC to express TVA and
rabies glycoprotein (RG) in these cells (Fig. 3B). Finally, we injected
SADΔG-EGFP (EnvA) (35) in the same region (LC) to label up-
stream neurons that make direct synaptic contact with LC-SC pro-
jection neurons. As expected, we found that some PLCβ4-expressing
PAG neurons expressed SADΔG-EGFP (Fig. 3C), indicating that
PLCβ4-expressing PAG neurons have monosynaptic connectivity to
LC neurons and suggesting that these PAG neurons directly regu-
late the LC-SC projection neurons.
Deletion of PLCβ4 Eliminates Opioid-Induced Suppression of Firing in
PAG-LC Projection Neurons. To define the physiological mechanism
underlying the enhanced opioid-mediated analgesia associated
with a PLCβ4 deficiency, we explored the physiological response
of PAG-LC projection neurons to opioids in brain slices. We fo-
cused on the caudal portion of the ventral region of the PAG
because it has been shown that cells in this region are sensitive to
morphine in vivo (36–38) and because retrogradely labeled
PAG-LC projection neurons were confined to this region (Fig. 4A).
Patch-clamp recording showed no difference in the resting
membrane potential of PAG-LC projection neurons between
wild-type (−42.82 ± 2.99 mV) and PLCβ4(−/−) (−41.11 ± 1.2
mV) mice. Moreover, neither wild-type nor PLCβ4(−/−) PAG-LC
projection neurons showed low-threshold spikes (LTSs) (Fig. 4 B
and D). Next, we recorded the discharge activity of PAG-LC
projection neurons at −35 mV for 1 min. The discharge activ-
ity of PAG-LC projection neurons under these conditions was
about ∼4 Hz, and there was no significant difference in this ac-
tivity between wild-type and PLCβ4(−/−) mice (Fig. 4 C and E).
However, there was a significant difference in sensitivity to the
endogenous opioid neurotransmitter, [met5]-enkephalin (ME),
between wild-type and PLCβ4-deficient neurons. ME is known to
be released by stress in vivo and inhibits neurons mainly through
μORs (4, 5, 39, 40). Wild-type PAG-LC projection neurons
quickly responded to application of ME (30 μM) with a re-
duction in discharge activity and became progressively hyper-
polarized (14.72 ± 2.84 mV) compared with untreated controls
(t = 4.389, P = 0.0070, paired two-tailed Student’s t test; Fig. 4 C
and F). In contrast, PLCβ4(−/−) PAG-LC projection neurons
exhibited no change in discharge activity or in the membrane
potential in response to the ME treatment (t = 0.197, P = 0.848,
paired two-tailed Student’s t test; Fig. 4 E and F). Consistent with
these results, treatment with the μOR agonist, [D-Ala(2),N-Me-
Phe(4),Gly(5)-ol]-enkephaline (DAMGO), suppressed the neuro-
nal activity of wild-type PAG-LC projection neurons but showed
no effect on PLCβ4(−/−) PAG-LC projection neurons (SI Appen-
dix, Fig. S9). To confirm that these results could not be attributed
to a change in μORs caused by deletion of PLCβ4, we immu-
nostained PAG-LC projection neurons for μORs. These experi-
ments show that expression of μORs in PAG-LC projection
neuron is not altered in PLCβ4(−/−) mice (t = 0.748, P = 0.456,
unpaired two-tailed Student’s t test; SI Appendix, Fig. S10). How-
ever, the response of the PAG-RVM projection neurons to the ME
treatment was not changed in both groups (SI Appendix, Fig. S11).
These findings suggest that PLCβ4 is required for the μOR-
dependent signal transduction that mediates suppression of PAG-
LC projection neurons. This, in turn, would lead to a decrease in the
activity of downstream target noradrenergic neurons in the LC,
resulting in a decrease in norepinephrine-dependent analgesia.
In the absence of PLCβ4, noradrenergic neurons in the LC would
remain active even in the presence of opioids, thus supporting
norepinephrine-dependent analgesia. The net result is an en-
hancement in opioid-induced analgesia at the systems level in
PLCβ4(−/−) mice compared with wild-type mice.
Enhanced Opioid-Dependent Analgesia in PLCβ4(−/−) Mice Is Reversed
by Antagonism of α2-Adrenergic Receptors. RVM-SC projection
neurons innervated the laminae I and II of the lumbar spinal
cord (41). Also, the LC is the principal noradrenergic nucleus in
the central nervous system and the main source of noradrenergic
innervation to the spinal dorsal horn, forming a well-described
Fig. 2. PLCβ4 is expressed in ventral PAG-LC but not in
PAG-RVM projection neurons. (A) Representative image
of cells in the PAG retrogradely labeled with two
different-color tracers. Schematic illustration of dual ret-
rograde tracing from both the LC and RVM (Inset). (B–D)
Zoomed view of the subcellular localization of CTB, flu-
orospheres, and PLCβ4 in the dorsal PAG (dPAG) (B),
lateral PAG (lPAG) (C), and ventral PAG (vPAG) (D). Ar-
rows indicate PLCβ4 immunoreactivity at LC retrogradely
labeled neurons. (Scale bars: A, 100 μm; B–D, 25 μm.)
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analgesic circuit (42, 43). We made the output of LC neurons
projecting to the SC to express fluorescence in a Cre-dependent
manner to substantiate that RVM and LC neurons engage SC in
different pathways (SI Appendix, Fig. S12A). Axonal terminals
from the LC were observed throughout the laminae I ∼ X of the
lumbar spinal cord, which made us propose that the targeting of
LC-SC neurons is different from that of the RVM-SC pathway
(SI Appendix, Fig. S12B).
In the SC, norepinephrine suppresses pain signals through
inhibitory actions on α2A-adrenoreceptors on central terminals
of primary afferent nociceptors (presynaptic inhibition), as well
as through direct α2-adrenergic actions on pain-relay neurons
(postsynaptic inhibition) (19, 20, 23, 24, 27, 44). If the enhanced
analgesic effect of locally or systemically infused morphine in
PLCβ4(−/−) mice were a direct result of the continuous LC ex-
citability cause by the persistent activity of PAG-LC projection
neurons, blocking the noradrenergic inputs in this mutant should
reverse the enhanced analgesic effect. First, we compared the c-
Fos expression level in the LC between the wild-type and the
PLCβ4(−/−) mice after the SSIA. As we expected, the PLCβ4(−/−)
mice showed more c-Fos signals in the LC than the wild-type
mice, implying hyperexcitability of the LC neurons in the mutant
mice. (t = 10.19, P < 0.001, unpaired two-tailed Student’s t test;
SI Appendix, Fig. S13 A and B) Next, we used idazoxan, an α2-
adrernergic receptor antagonist, that does not interfere with the
morphine effect (45). i.p. administration of idazoxan (20 mg/kg)
did not affect the basal thermal sensitivity in wild-type (t = 0.103,
P = 0.919, unpaired two-tailed Student’s t test) or PLCβ4(−/−)
TH-cre Lumbar spinal cord
SADΔG-EGFP
AAV-FLEXFRT-G
AAV-FLEXFRT-TC
CAV2-FLEX-Flp
GFP 
A
B
C
Fig. 3. Transsynaptic tracing of PAG→ LC to LC→ SC
circuit by cTRIO. (A) Schematic depiction of experi-
mental procedure. CAV2-FLEX (loxP)-Flp was injected
into the SC of TH-Cre mice to express Flp in LC neu-
rons that send projections to the PAG (day 1). Flp-
dependent AAV carrying TVA, and RG were then
injected into the LC (day 1). SADΔG-EGFP (EnvA) was
injected into the same site (day 15). (B, Left) Distri-
bution of the starter cells (TVA+, SADΔG+ cells) in the
LC region. (B, Right) Magnifications of regions in
white rectangles in images (yellow arrows). (C, Left)
PLCβ4-expressing PAG neurons merged with the
SADΔG+EGFP signals. (C, Right) Magnifications of
regions in white rectangles in images (white arrows).
Fig. 4. Discharge activities at depolarized mem-
brane potential in the LC-projecting neurons of the
ventral PAG. (A, Left) Schematic depiction of retro-
grade labeling in the LC and patch-clamp recordings
of cells in the PAG. (A, Right three images) DIC image
(Left and Middle) and retrograde dye image of a
patched neuron in the ventral PAG (vPAG; Right).
Red circle indicates an example of PAG-LC projection
neurons. (Scale bars: A,Middle Left, 500 μm;A,Middle
Right and Right, 25 μm.) (B and D) Electrophysiological
analysis of LTS in PAG-LC projection neurons from
wild-type (B) and PLCβ4(−/−) (D) mice in response to
hyperpolarizing current pulses. (C and E) Changes in
firing patterns for two periods from PAG-LC pro-
jection neurons from wild-type (C) and PLCβ4(−/−) (E)
mice. (F) Comparison of discharge activity before and
after treatment with ME between in wild-type and
PLCβ4(−/−) PAG-LC projection neurons. Values are
means ± SEM. (***P< 0.001; n.s., not significant.)
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mice (t = 0.137, P = 0.893, unpaired two-tailed Student’s t test)
(SI Appendix, Fig. S14A). We subsequently infused morphine (10
mg/kg) in combination with a systemic injection of idazoxan to
block α2-adrenergic receptor activation. As expected, idazoxan
did not influence the analgesic effect of morphine in the wild-
type mice, as measured by RM ANOVA (F1,25 = 2.735, P =
0.1107, Fig. 5A) or unpaired Student’s t test (t = 1.696, P = 0.102,
SI Appendix, Fig. S14B). Notably, in mutant mice, a systemic
injection of idazoxan significantly reduced morphine-induced
analgesia compared with morphine alone, resulting in a nearly
complete reversal of the potentiated analgesia to wild-type levels
(F1,16 = 126.2, P < 0.001, RM ANOVA, Fig. 5A; t = 14.78, P <
0.001, unpaired two-tailed Student’s t test; SI Appendix, Fig.
S14B). Next, we systemically injected idazoxan together with
PAG-specific morphine infusion in both wild-type and PLCβ4-
deficient mouse groups. Systemic idazoxan injection did not af-
fect the analgesia induced by PAG-specific morphine infusion
analgesia in wild-type mice (F1,26 = 0.3768, P = 0.5447, RM
ANOVA, Fig. 5B; t = 0.424, P = 0.674, unpaired two-tailed Stu-
dent’s t test, SI Appendix, Fig. S14C). However, the increased PAG-
specific morphine-induced analgesia observed in the PLCβ4(−/−)
mice was returned to wild-type levels by i.p. injected idazoxan
(F1,23 = 7.678, P = 0.0109, RM ANOVA, Fig. 4B; t = 5.066, P <
0.001, unpaired two-tailed Student’s t test, SI Appendix, Fig. S14C).
Taken together, these results indicate that the persistent ac-
tivity of LC neurons is responsible for the augmented opioid-
induced analgesia in PLCβ4(−/−) mice.
Discussion
Yin-and-Yang PAG Bifurcation Model. Our data suggest that the
stress-induced, opioid-dependent, descending analgesia circuits
bifurcate at the PAG into two mutually exclusive pathways that
exert opposite effects: The PAG-RVM projection enhances, and
the PAG-LC projection suppresses, the descending analgesia
(Fig. 6, Left and Middle).
The most investigated form of the physiological activation of
opioid-linked pain-modulating circuits originates under the
general framework of stress-induced analgesia (7, 46). The midbrain
PAG was the first discovered descending pain-modulating site in the
brain, and the PAG-RVM circuits project to the dorsal horn of the
SC and the trigeminal nucleus caudalis, where pain-transmitting
neurons are located. In the disinhibition model, opioids activate
the PAG–RVM descending pathway via suppression of the in-
hibitory influence of local GABAergic interneurons, thereby en-
hancing the antinociceptive drive of the neuronal output to the SC
(9, 10). Now the results in this paper reveal the complex
organization of the PAG with regard to the control of the stress-
induced opioid-dependent descending analgesia. Thus, opioid can
both enhance and suppress the descending analgesia.
The Opioid Circuits in the PAG, a Safeguard Against the Adverse
Effect of Stress. The LC is activated by physiological and envi-
ronmental stressors and is thought to play a role in cognitive
aspects of the stress response (47). Corticotropin-releasing factor
(CRF) acts through activation of the LC-norepinephrine (NE)
system to increase the LC neuronal firing rate, thereby contrib-
uting to coordination of physiological and behavioral responses to
stress (48, 49). Apart from the well-known descending LC-spinal
pathway, which is important for pain control, an increase in LC
discharge under stress conditions could potentially lead to a seri-
ous autonomic failure such as hypertensive challenge (50, 51). Our
results suggest that endogenous opioids may serve to counterbal-
ance the adverse effect of stress on the LC–NE system, while
achieving analgesia.
Phospholipase C Signaling in the Opioid-Induced Analgesia. Pre-
viously, we have reported that the thalamic PLCβ4 regulates the
firing properties of thalamocortical neurons through a mecha-
nism mediated by T-type calcium channels (15). Interestingly,
PAG-LC projection neurons showed no LTS responses, and
their firing was not attenuated by the opioids in the absence of
PLCβ4 (Fig. 3). These observations demonstrate that PLCβ4 is
required for fine control of opioid responses in the descending
pain pathway. Indeed, numerous studies have reported that the
PLCβ isoforms are activated by the Gβγ, which is liberated by
μORs activation, and induce IP3 and diacylglycerol formation. This,
in turn, results in intracellular Ca2+ release from IP3-sensitive Ca
2+
stores, PKC activation, and VDCC inhibition (52–57). These con-
clusions are consistent with prevailing views regarding the impor-
tance of the PLC system in opioid-signaling pathways (58, 59).
Additional studies will be required to define the anti-
nociceptive function of other PLC systems in the PAG during the
pain transmission. Importantly, our findings suggest that the
A B
Fig. 5. The reversed opioidergic analgesia by antagonizing systemic α2-
adrenergic receptors in PLCβ4 mice. (A) Time course of the analgesic ef-
fects of idazoxan and morphine in the wild-type and in the PLCβ4 mutant
mice by systemic treatment. (B) Time course of the analgesic effects of i.p.
injected idazoxan with the PAG-specific delivery of morphine in both the
wild-type and the PLCβ4 mutant mice. Values are means ± SEM (*P< 0.05;
**P< 0.01; ***P < 0.001).
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Fig. 6. Working model of the PAG descending pain-gating pathway for the
opioid analgesic circuitry. (Left) The two distinct pathways in the PAG bi-
furcation model: PAG-RVM projection neurons and PAG-LC projection neu-
rons. (Middle) The physiological role of the PAG-RVM pathway in positive
control of analgesia (⊕) proposed in the disinhibition model, and the new
proposed model of the PAG-LC pathway for negative control of anti-
nociceptive effects (⊖) in wild-type mice. (Right) PAG-LC excitatory trans-
mission showed persistent activity under opioidergic conditions in PLCβ4(−/−)
mice, leading to an enhanced analgesic effect. The thickness of the arrows
indicates the relative activity of individual transmissions.
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current “Yin-and-Yang” model at the PAG provides a thera-
peutic target in pain control (Fig. 6, Right).
Materials and Methods
Animal care and all experiments were conducted in accordance with the
Institutional Review Board of Institute for Basic Science (IBS), Korea for the
ethical guidelines of Animal Care and Use. Detailed descriptions of study
methods are provided in SI Appendix, Materials and Methods.
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